| 000 | 01507 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516172123.0 | ||
| 264 | 0 | _c20131114 | |
| 008 | 201311s 0 0 eng d | ||
| 022 | _a0392-856X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHorneff, Gerd | |
| 245 | 0 | 0 |
_aMacrophage activation syndrome as the initial manifestation of tumour necrosis factor receptor 1-associated periodic syndrome (TRAPS). _h[electronic resource] |
| 260 |
_bClinical and experimental rheumatology _c |
||
| 300 |
_a99-102 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aCyclosporine _xtherapeutic use |
| 650 | 0 | 4 | _aDNA Mutational Analysis |
| 650 | 0 | 4 |
_aDexamethasone _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEtoposide _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFever |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 |
_aHereditary Autoinflammatory Diseases _xcomplications |
| 650 | 0 | 4 | _aHeredity |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aMacrophage Activation Syndrome _xdiagnosis |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aPedigree |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor, Type I _xgenetics |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aRhouma, Asma | |
| 700 | 1 | _aWeber, Carola | |
| 700 | 1 | _aLohse, Peter | |
| 773 | 0 |
_tClinical and experimental rheumatology _gvol. 31 _gno. 3 Suppl 77 _gp. 99-102 |
|
| 999 |
_c23115119 _d23115119 |
||